Record High: E-cigarette Use in the UK Up 10-fold in 10 Years

Aug.29.2022
Record High: E-cigarette Use in the UK Up 10-fold in 10 Years
A report shows e-cigarette usage has rapidly risen in the UK, with an estimated 4.3 million regular users.

A report has revealed that over the past decade, the use of electronic cigarettes has rapidly increased in the UK, reaching a record high with an estimated 4.3 million individuals regularly using e-cigarettes. Data suggests that 8.3% of adults in England, Wales, and Scotland are e-cigarette users, a significant increase from 1.7% ten years ago, which accounts for approximately 800,000 individuals using e-cigarettes. The report was conducted by Action on Smoking and Health (ASH), who suggest that over the past decade, there has been an 'e-cigarette revolution.'


Hazel Cheeseman, Deputy CEO of Ash, has stated that the increasing number of smokers switching to electronic cigarettes is "good news".


For those trying to quit smoking, they can be a lifesaving tool. However, relying solely on vaping to solve smoking addiction is not the answer. We must address the recent rise of young people vaping and implement broader efforts to combat smoking, as e-cigarettes are not suitable for everyone. It is time for the government to take action," she said.


According to a report, out of the 4.3 million e-cigarette users, approximately 2.4 million were previous smokers, 1.5 million were current smokers, and 350,000 had never smoked before. Cheeseman stated that e-cigarettes among the latter group are often "rare" and "experimental." The report showed that e-cigarettes have become particularly popular among young adults, with those aged 18 to 24 being the largest consumer group in 2022, accounting for 11%. This number has been growing since 2021 when their e-cigarette usage was at its lowest, at 5%. The rate among those aged 55 and above is the lowest, at 5.9%.


Cheeseman expressed concern, particularly in light of early research showing that the use of e-cigarettes among 11 to 17-year-olds has risen from 4% in 2020 to 7% in 2022, despite the fact that selling e-cigarettes to those under 18 is illegal. However, the research also indicates a decrease in smoking rates with the increase in e-cigarette use. The report is based on the annual Smokefree GB survey conducted by YouGov among over 13,000 adults from across the UK and found that 28% of current smokers have never tried e-cigarettes, 21% said they did not want to replace one addiction with another, 23% thought e-cigarette use was not similar enough to smoking, and 10% were "concerned about the safety of e-cigarettes”. A third of adults believed that e-cigarettes were either more harmful than smoking or equally harmful, which the report's authors say is incorrect.


In 2022, 35% of current e-cigarette users also smoke traditional cigarettes. Among this group, those who use e-cigarettes daily smoke fewer traditional cigarettes than those who use them infrequently.


Statement


This article is compiled from third-party information and is intended for industry communication and learning purposes.


This article does not represent the views of 2FIRSTS, and 2FIRSTS cannot confirm the truthfulness and accuracy of the content. The translation of this article is only intended for industry exchange and research.


Due to limited translation ability, the translated article may not fully express the same meaning as the original. Please refer to the original article for accuracy.


2FIRSTS fully aligns its statements and positions regarding domestic, Hong Kong, Macau, Taiwan, and foreign affairs with that of the Chinese government.


The copyright of the compiled information belongs to the original media and author. If there is any infringement, please contact us for deletion.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
FDA Unifies Tobacco Registration and Product Listing Form Across Product Categories
The U.S. FDA has consolidated two tobacco establishment registration and product listing forms into a redesigned Form FDA 3741 covering all regulated product categories, including e-cigarettes, heated tobacco products and nicotine pouches. The current requirements remain limited to domestic establishments. Separately, the FDA has proposed extending registration and product listing requirements to foreign manufacturers, signaling greater regulatory attention to manufacturing entities and product-level information across the tobacco and nicotine supply chain.
FDA
Sep.30
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus Enters Japan’s FamilyMart Network With Zero-Nicotine NEO Line and Kishidan Campaign
Snowplus distributor H&S said the zero-nicotine, zero-tar NEO vaping line will begin rolling out across FamilyMart stores in Japan from September 14, 2026, excluding some locations. The DASH line will also be sold at selected FamilyMart stores in southern Kyushu and Okinawa. Snowplus simultaneously named Japanese rock band Kishidan as a brand ambassador, combining convenience-store distribution with a broader consumer marketing push in Japan.
Sep.15
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As Regulators Focus on Nicotine Pouch Child Safety, Safeguard Pursues an External Packaging Route
As regulators pay closer attention to child safety in nicotine pouches, manufacturers face a practical challenge: how to strengthen child-resistant packaging without unnecessarily reworking products, production lines and regulatory submissions already in place. In a written interview with 2Firsts, Chemular detailed Safeguard’s external packaging approach, its customer-specific testing requirements and possible PMTA pathways. The model remains early-stage, but it offers a new way to think about an increasingly important regulatory and manufacturing issue.
Industry Insight
Sep.19
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden Finds ZYN Ingredient Labels Noncompliant Over Generic Flavoring Disclosure, Swedish Match Faces SEK 2 Million Monthly Penalty
Sweden's Public Health Agency has found ingredient labels on ZYN nicotine pouches sold by Philip Morris International subsidiary Swedish Match to be noncompliant, according to Dagens industri. The products' packaging listed 10 to 13 ingredients, compared with 11 to 42 in regulatory submissions, with multiple flavoring ingredients grouped under the generic term "aromer." The agency ordered corrective action, warning of a conditional penalty of SEK 2 million per month for noncompliance. The order applies only to products manufactured after the decision becomes legally effective and does not require recalls. Swedish Match disputes the agency's interpretation and plans to appeal.
PMI
Oct.22
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
GAO Audit Finds Nearly 132,000 FDA Tobacco Applications Waiting an Average 1,266 Days as Nicotine Pouch Pilot Practices Move Into Vape PMTA Reviews
A U.S. Government Accountability Office audit found that 131,915 tobacco product applications submitted to the FDA since 2018 remained without a final review as of December 31, 2025, with pending applications waiting an average of 1,266 days. GAO also found FDA lacks the data needed to systematically determine whether scientific reviews meet applicable timelines. HHS agreed to upgrade the agency's tracking systems. At the same time, FDA has begun applying lessons from its nicotine pouch PMTA pilot to e-cigarette reviews, while changes to enforcement policy and electronic submissions are making the specific stage of a PMTA increasingly relevant to market access.
FDA
Oct.03
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
IQOS Enters Kantar BrandZ Global Top 100 for First Time, Valued at $36.6 Billion and Ranked No. 74
Philip Morris International’s IQOS has entered the Kantar BrandZ Top 100 Most Valuable Global Brands for the first time, ranking No. 74 with a brand value of $36.634 billion and becoming one of only three newcomers to the 2026 ranking. Kantar said the combined value of the Global Top 100 reached $13.1 trillion, up 22% year on year, while the threshold for entry rose to a record high. PMI says IQOS has more than 35 million users worldwide and surpassed $10 billion in annual net revenues within a decade of launch.
Sep.03